Reirradiation and Erbitux in the HNSCC

NCT01237483 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer Squamous Cell

Interventions

DRUG: Erbitux

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou